Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Charles Hicks

    TitleProfessor Of Clinical
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address200 W. Arbor Drive #8681
    CA San Diego 92103
    Phone619-543-3995
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Gay CL, Willis SJ, Cope AB, Kuruc JD, McGee KS, Sebastian J, Crooks AM, McKellar MS, Margolis DM, Fiscus SA, Hicks C, Ferrari G, Eron JJ. Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. AIDS. 2016 Nov 28; 30(18):2815-2822. PMID: 27662549.
        View in: PubMed
      2. Katrak S, Park LP, Woods C, Muir A, Hicks C, Naggie S. Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease. Open Forum Infect Dis. 2016 Sep; 3(3):ofw173. PMID: 27704025.
        View in: PubMed
      3. Clement ME, Hicks C. Syphilis on the Rise: What Went Wrong? JAMA. 2016 Jun 7; 315(21):2281-3. PMID: 27272579.
        View in: PubMed
      4. Okeke NL, Hicks C, McKellar MS, Fowler VG, Federspiel JJ. History of AIDS in HIV-Infected Patients Is Associated With Higher In-Hospital Mortality Following Admission for Acute Myocardial Infarction and Stroke. J Infect Dis. 2016 Jun 15; 213(12):1955-61. PMID: 26941281.
        View in: PubMed
      5. Tebas P, Kumar P, Hicks C, Granier C, Wynne B, Min S, Pappa K. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 2015 Nov 28; 29(18):2459-64. PMID: 26355674.
        View in: PubMed
      6. Okeke NL, Chin T, Clement M, Chow SC, Hicks C. Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis. AIDS Care. 2016 Apr; 28(4):475-82. PMID: 26479580.
        View in: PubMed
      7. Clement ME, Okeke NL, Hicks C. Fever and Rash in a Patient With Hepatitis. JAMA. 2015 Jul 28; 314(4):400-1. PMID: 26219059.
        View in: PubMed
      8. Naggie S, Patel K, Yang LY, Chow SC, Johnson V, Guyton JR, Muir AJ, Sulkowski M, Hicks C. Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals. Open Forum Infect Dis. 2015 Apr; 2(2):ofv066. PMID: 26110167.
        View in: PubMed
      9. Clement ME, Okeke NL, Hicks C. Treatment of late-stage syphilis--reply. JAMA. 2015 Mar 3; 313(9):969-70. PMID: 25734743.
        View in: PubMed
      10. Darquenne C, Hicks C, Malhotra A. Last Word on Viewpoint: The ongoing need for good physiological investigation: Obstructive sleep apnea in HIV patients as a paradigm. J Appl Physiol (1985). 2015 Jan 15; 118(2):251. PMID: 25593221.
        View in: PubMed
      11. Clement ME, Okeke NL, Hicks C. Treatment of syphilis: a systematic review. JAMA. 2014 Nov 12; 312(18):1905-17. PMID: 25387188.
        View in: PubMed
      12. Clement ME, Hicks C. RPR and the serologic diagnosis of syphilis. JAMA. 2014 Nov 12; 312(18):1922-3. PMID: 25387191.
        View in: PubMed
      13. Bloomfield GS, Khazanie P, Morris A, Rabadán-Diehl C, Benjamin LA, Murdoch D, Radcliff VS, Velazquez EJ, Hicks C. HIV and Noncommunicable Cardiovascular and Pulmonary Diseases in Low- and Middle-Income Countries in the ART Era: What We Know and Best Directions for Future Research. J Acquir Immune Defic Syndr. 2014 Sep 1; 67 Suppl 1:S40-53. PMID: 25117960.
        View in: PubMed
      14. Darquenne C, Hicks C, Malhotra A. The ongoing need for good physiological investigation: obstructive sleep apnea in HIV patients as a paradigm. J Appl Physiol (1985). 2015 Jan 15; 118(2):244-6. PMID: 25150224.
        View in: PubMed
      15. Milligan C, Cuneo CN, Rutstein SE, Hicks C. "Know Your Status": results from a novel, student-run HIV testing initiative on college campuses. AIDS Educ Prev. 2014 Aug; 26(4):317-27. PMID: 25068179.
        View in: PubMed
      16. Cope AB, Crooks AM, Chin T, Kuruc JD, McGee KS, Eron JJ, Hicks C, Hightow-Weidman LB, Gay CL. Incident Sexually Transmitted Infection as a Biomarker for High-Risk Sexual Behavior After Diagnosis of Acute HIV. Sex Transm Dis. 2014 Jul; 41(7):447-52. PMID: 24922104.
        View in: PubMed
      17. Bruno TO, Hicks C, Naggie S, Wohl DA, Albrecht H, Thielman NM, Rabin DU, Layton S, Subramaniam C, Grichnik KP, Shlien A, Weyer D. VISION: A Regional Performance Improvement Initiative for HIV Health Care Providers. J Contin Educ Health Prof. 2014 Jun; 34(3):171-8. PMID: 25258129.
        View in: PubMed
      18. Goswami ND, Tsalik EL, Naggie S, Miller WC, Horton JR, Pfeiffer CD, Hicks C. A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design. Trials. 2014; 15(1):31. PMID: 24450313.
        View in: PubMed
      19. Hicks C. Updated recommendations on INSTI-based regimens for ART-naive patients. J Watch AIDS Clin Care. 2013 Dec; 25(12):89. PMID: 26204591.
        View in: PubMed
      20. Hurt CB, Sebastian J, Hicks C, Eron JJ. Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009-2012. Clin Infect Dis. 2014 Feb; 58(3):423-31. PMID: 24145878.
        View in: PubMed
      21. Wohl DA, Arnoczy G, Fichtenbaum CJ, Campbell T, Taiwo B, Hicks C, McComsey GA, Koletar S, Sax P, Tebas P, Ha B, Massengale K, Walsh K, Stein JH. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther. 2014; 19(2):141-7. PMID: 23985706.
        View in: PubMed
      22. Chin T, Hicks C, Samsa G, McKellar M. Diagnosing HIV infection in primary care settings: missed opportunities. AIDS Patient Care STDS. 2013 Jul; 27(7):392-7. PMID: 23802143.
        View in: PubMed
      23. Vinikoor MJ, Cope A, Gay CL, Ferrari G, McGee KS, Kuruc JD, Lennox JL, Margolis DM, Hicks C, Eron JJ. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr. 2013 Apr 15; 62(5):505-8. PMID: 23314410.
        View in: PubMed
      24. Mills AM, Antinori A, Clotet B, Fourie J, Herrera G, Hicks C, Madruga JV, Vanveggel S, Stevens M, Boven K. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks. HIV Med. 2013 Aug; 14(7):391-400. PMID: 23298380.
        View in: PubMed
      25. Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses. 2013 Mar; 29(3):435-40. PMID: 23072344.
        View in: PubMed
      26. McKellar MS, Cope AB, Gay CL, McGee KS, Kuruc JD, Kerkau MG, Hurt CB, Fiscus SA, Ferrari G, Margolis DM, Eron JJ, Hicks C. Acute HIV-1 infection in the Southeastern United States: a cohort study. AIDS Res Hum Retroviruses. 2013 Jan; 29(1):121-8. PMID: 22839749.
        View in: PubMed
      27. Hicks C, Clay P, Redfield R, Lalezari J, Liporace R, Schneider S, Sension M, McRae M, Laurent JP. Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects. AIDS Res Hum Retroviruses. 2013 Feb; 29(2):250-5. PMID: 22738014.
        View in: PubMed
      28. Arnoczy GS, Ferrari G, Goonetilleke N, Corrah T, Li H, Kuruc J, Schmitz JL, McGee K, Hicks C, Eron JJ. Massive CD8 T cell response to primary HIV infection in the setting of severe clinical presentation. AIDS Res Hum Retroviruses. 2012 Aug; 28(8):789-92. PMID: 22011008.
        View in: PubMed
      29. Frahm MA, Picking RA, Kuruc JD, McGee KS, Gay CL, Eron JJ, Hicks C, Tomaras GD, Ferrari G. CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. J Immunol. 2012 May 1; 188(9):4289-96. PMID: 22461689.
        View in: PubMed
      30. Person AK, Hicks C. Pre-exposure prophylaxis--one more tool for HIV prevention. Curr HIV Res. 2012 Mar; 10(2):117-22. PMID: 22329517.
        View in: PubMed
      31. Hicks C. HIV treatment as prevention--the time is now. J Watch AIDS Clin Care. 2012 Jan; 24(1):1. PMID: 26223035.
        View in: PubMed
      32. Hicks C. Growing the intense inhibitor class--Elvitegravir and Dolutegravir. J Watch AIDS Clin Care. 2012 Jan; 24(1):5-6. PMID: 26223043.
        View in: PubMed
      33. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T, Gaschen B, Krishnamoorthy M, Li H, Decker JM, Salazar-Gonzalez JF, Wang S, Jiang C, Gao F, Swanstrom R, Anderson JA, Ping LH, Cohen MS, Markowitz M, Goepfert PA, Saag MS, Eron JJ, Hicks C, Blattner WA, Tomaras GD, Asmal M, Letvin NL, Gilbert PB, Decamp AC, Magaret CA, Schief WR, Ban YE, Zhang M, Soderberg KA, Sodroski JG, Haynes BF, Shaw GM, Hahn BH, Korber B. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 2011 Sep; 7(9):e1002209. PMID: 21980282.
        View in: PubMed
      34. Okeke NL, Hicks C. Role of raltegravir in the management of HIV-1 infection. HIV AIDS (Auckl). 2011; 3:81-92. PMID: 22096410.
        View in: PubMed
      35. Gay C, Dibben O, Anderson JA, Stacey A, Mayo AJ, Norris PJ, Kuruc JD, Salazar-Gonzalez JF, Li H, Keele BF, Hicks C, Margolis D, Ferrari G, Haynes B, Swanstrom R, Shaw GM, Hahn BH, Eron JJ, Borrow P, Cohen MS. Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One. 2011; 6(5):e19617. PMID: 21573003.
        View in: PubMed
      36. Hicks C. Investigational antiretrovirals--the pipeline is not dry. J Watch AIDS Clin Care. 2011 May; 23(5):39. PMID: 27652428.
        View in: PubMed
      37. Gay CL, Mayo AJ, Mfalila CK, Chu H, Barry AC, Kuruc JD, McGee KS, Kerkau M, Sebastian J, Fiscus SA, Margolis DM, Hicks C, Ferrari G, Eron JJ. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS. 2011 Apr 24; 25(7):941-9. PMID: 21487250.
        View in: PubMed
      38. Wang D, Hicks C, Goswami ND, Tafoya E, Ribeiro RM, Cai F, Perelson AS, Gao F. Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. J Virol. 2011 Jul; 85(13):6403-15. PMID: 21490094.
        View in: PubMed
      39. Liu J, Miller MD, Danovich RM, Vandergrift N, Cai F, Hicks C, Hazuda DJ, Gao F. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother. 2011 Mar; 55(3):1114-9. PMID: 21173185.
        View in: PubMed
      40. Hicks C. Cyclosporine in acute and early HIV infection. J Watch AIDS Clin Care. 2010 Jun; 22(6):54-5. PMID: 20669362.
        View in: PubMed
      41. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, Learn GH, Morgan CJ, Schumacher JE, Hraber P, Giorgi EE, Bhattacharya T, Korber BT, Perelson AS, Eron JJ, Cohen MS, Hicks C, Haynes BF, Markowitz M, Keele BF, Hahn BH, Shaw GM. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog. 2010 May; 6(5):e1000890. PMID: 20485520.
        View in: PubMed
      42. Naggie S, Hicks C. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. J Antimicrob Chemother. 2010 Jun; 65(6):1094-9. PMID: 20418273.
        View in: PubMed
      43. Hicks C. Report from the 17th Conference on Retroviruses and Opportunistic Infections. Intensification of ART--no demonstrable benefit. J Watch AIDS Clin Care. 2010 Apr; 22(4):31. PMID: 20480929.
        View in: PubMed
      44. Hicks C. Report from the 17th Conference on Retroviruses and Opportunistic Infections. Four antiretrovirals in one? J Watch AIDS Clin Care. 2010 Apr; 22(4):30-1. PMID: 20480618.
        View in: PubMed
      45. Taiwo B, Hicks C, Eron J. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1. J Antimicrob Chemother. 2010 Jun; 65(6):1100-7. PMID: 20348088.
        View in: PubMed
      46. Hicks C. Definitive results: IL-2 does not benefit HIV-infected patients. Interleukin-2 improves CD4-cell recovery in patients on antiretroviral therapy, but that benefit does not translate into lower risks for disease or death. J Watch AIDS Clin Care. 2010 Jan; 22(1):4. PMID: 20617576.
        View in: PubMed
      47. Naggie S, Hseih T, Reckleff J, Castellano J, Hicks C. Treatment and CD4+ T cell count recovery among antiretroviral therapy-naive patients with HIV/AIDS. Clin Infect Dis. 2009 Nov 15; 49(10):1619-20. PMID: 19857170.
        View in: PubMed
      48. Hicks C. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Strategies for antiretroviral deintensification. J Watch AIDS Clin Care. 2009 Oct; 21(10):81-2. PMID: 20461844.
        View in: PubMed
      49. Hicks C. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. GSK572--a "next generation" integrase inhibitor? J Watch AIDS Clin Care. 2009 Oct; 21(10):80-1. PMID: 20461843.
        View in: PubMed
      50. Wolfe C, Hicks C. Profile of darunavir in the management of treatment-experienced HIV patients. HIV AIDS (Auckl). 2009; 1:13-21. PMID: 22096376.
        View in: PubMed
      51. Lakey W, Hicks C. Lipid changes associated with antiretroviral therapy: results differ by reporting approach. Curr HIV Res. 2009 Sep; 7(5):547-54. PMID: 19534666.
        View in: PubMed
      52. Bonsignori M, Moody MA, Parks RJ, Holl TM, Kelsoe G, Hicks C, Vandergrift N, Tomaras GD, Haynes BF. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol. 2009 Aug 15; 183(4):2708-17. PMID: 19625640.
        View in: PubMed
      53. Levesque MC, Moody MA, Hwang KK, Marshall DJ, Whitesides JF, Amos JD, Gurley TC, Allgood S, Haynes BB, Vandergrift NA, Plonk S, Parker DC, Cohen MS, Tomaras GD, Goepfert PA, Shaw GM, Schmitz JE, Eron JJ, Shaheen NJ, Hicks C, Liao HX, Markowitz M, Kelsoe G, Margolis DM, Haynes BF. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 2009 Jul 7; 6(7):e1000107. PMID: 19582166.
        View in: PubMed
      54. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, Hicks C, Owzar K, Tomaras GD, Montefiori DC, Haynes BF, Delfraissy JF. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS. 2009 May 15; 23(8):897-906. PMID: 19414990.
        View in: PubMed
      55. Hicks C, DeJesus E, Sloan LM, Sension MG, Wohl DA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT. Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Hum Retroviruses. 2009 Apr; 25(4):395-403. PMID: 19320570.
        View in: PubMed
      56. Hicks C. Report from the 16th Conference on Retroviruses and Opportunistic Infections. Investigational pharmacologic boosters. J Watch AIDS Clin Care. 2009 Apr; 21(4):33-4. PMID: 19548333.
        View in: PubMed
      57. Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1; 48(7):931-9. PMID: 19231980.
        View in: PubMed
      58. Hicks C. Report from the 16th Conference on Retroviruses and Opportunistic Infections. Timing of ART initiation--still no definitive answers. J Watch AIDS Clin Care. 2009 Apr; 21(4):30. PMID: 19544614.
        View in: PubMed
      59. Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks C, Klein CE, Chiu YL, King MS, Bernstein BM. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine. AIDS Res Hum Retroviruses. 2009 Mar; 25(3):269-75. PMID: 19292590.
        View in: PubMed
      60. Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks C, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol. 2009 Apr; 83(8):3617-25. PMID: 19193787.
        View in: PubMed
      61. Hurt CB, McCoy SI, Kuruc J, Nelson JA, Kerkau M, Fiscus S, McGee K, Sebastian J, Leone P, Pilcher C, Hicks C, Eron J. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther. 2009; 14(5):673-8. PMID: 19704170.
        View in: PubMed
      62. Hicks C. Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimens. AIDS Clin Care. 2009 Jan; 21(1):3. PMID: 19219957.
        View in: PubMed
      63. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks C, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008 Dec; 82(24):12449-63. PMID: 18842730.
        View in: PubMed
      64. Hicks C. Guideline watch. Antiretroviral drug resistance testing--updated guidelines from the IAS-USA. AIDS Clin Care. 2008 Aug; 20(8):64. PMID: 18814369.
        View in: PubMed
      65. Hanson KE, Reckleff J, Hicks L, Castellano C, Hicks C. Unsuspected HIV infection in patients presenting with acute meningitis. Clin Infect Dis. 2008 Aug 1; 47(3):433-4. PMID: 18605915.
        View in: PubMed
      66. Simpson KN, Roberts G, Hicks C, Finnern HW. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials. 2008 Jul-Aug; 9(4):225-37. PMID: 18753117.
        View in: PubMed
      67. Lalani T, Hicks C. Does antiretroviral therapy prevent HIV transmission to sexual partners? Curr Infect Dis Rep. 2008 May; 10(2):140-5. PMID: 18462589.
        View in: PubMed
      68. Hicks C. Report from the 15th Retrovirus Conference. Is abacavir therapy associated with MI risk? AIDS Clin Care. 2008 Apr; 20(4):29. PMID: 19266668.
        View in: PubMed
      69. Murphy RL, da Silva BA, Hicks C, Eron JJ, Gulick RM, Thompson MA, McMillan F, King MS, Hanna GJ, Brun SC. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials. 2008 Jan-Feb; 9(1):1-10. PMID: 18215977.
        View in: PubMed
      70. Walmsley SL, Cotte L, Rusconi S, Ward DJ, Hicks C, Meier U, Valdez H, Boucher CA. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. AIDS. 2007 Oct 18; 21(16):2245-8. PMID: 18090054.
        View in: PubMed
      71. Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, Sutherland LL, Gorny MK, Zolla-Pazner S, Vanleeuwen S, Moody MA, Xia SM, Montefiori DC, Tomaras GD, Weinhold KJ, Karim SA, Hicks C, Liao HX, Robinson J, Shaw GM, Haynes BF. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol. 2008 Jan; 82(1):115-25. PMID: 17942537.
        View in: PubMed
      72. Hicks C. Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Acyclovir to prevent HIV infection? AIDS Clin Care. 2007 Oct; 19(10):84-5. PMID: 18398997.
        View in: PubMed
      73. Hicks C, Gay C, Ferrari G. Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses. Clin Exp Immunol. 2007 Aug; 149(2):211-6. PMID: 17590167.
        View in: PubMed
      74. Lalani T, Hicks C. Does antiretroviral therapy prevent HIV transmission to sexual partners? Curr HIV/AIDS Rep. 2007 May; 4(2):80-5. PMID: 17547829.
        View in: PubMed
      75. Mugavero MJ, Castellano C, Edelman D, Hicks C. Late diagnosis of HIV infection: the role of age and sex. Am J Med. 2007 Apr; 120(4):370-3. PMID: 17398235.
        View in: PubMed
      76. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS. 2007 Mar 30; 21(6):F1-10. PMID: 17413684.
        View in: PubMed
      77. Taiwo BO, Hicks C. Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance. AIDS Read. 2007 Mar; 17(3):151-6, 159-61. PMID: 17396332.
        View in: PubMed
      78. Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, Glesby M, Gulick R, Hicks C, Kessler H, Murphy R, Thompson M, White AC, Wolfe P, McMillan FI, Hanna GJ. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007 Mar 1; 44(5):749-54. PMID: 17278071.
        View in: PubMed
      79. Cai F, Chen H, Hicks C, Bartlett JA, Zhu J, Gao F. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods. 2007 Feb; 4(2):123-5. PMID: 17206150.
        View in: PubMed
      80. Hicks C. Report from the XVI International AIDS Conference. Integrase inhibitors. AIDS Clin Care. 2006 Nov; 18(11):101. PMID: 17183747.
        View in: PubMed
      81. Hicks C. Management of the highly experienced patient. Curr Opin HIV AIDS. 2006 Sep; 1(5):424-9. PMID: 19372842.
        View in: PubMed
      82. Hicks C, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006 Aug 5; 368(9534):466-75. PMID: 16890833.
        View in: PubMed
      83. Hanson K, Hicks C. New antiretroviral drugs. Curr HIV/AIDS Rep. 2006 Jul; 3(2):93-101. PMID: 16608666.
        View in: PubMed
      84. Hicks C. Report from the 13th retrovirus conference. New data on TMC114 and TMC125. AIDS Clin Care. 2006 Apr; 18(4):34. PMID: 16718876.
        View in: PubMed
      85. Hicks C. Report from the 13th retrovirus conference. Integrase inhibitors on the way. AIDS Clin Care. 2006 Apr; 18(4):33-4. PMID: 16718875.
        View in: PubMed
      86. Hicks C, Nagy GS, Koutkia-Mylonakis P. Antiretroviral rounds. Entrance left: the endocrinologist. AIDS Clin Care. 2006 Feb; 18(2):18-9. PMID: 16555392.
        View in: PubMed
      87. Hicks C. Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states. AIDS Read. 2005 Dec; 15(12):683-6, 689-90. PMID: 16355598.
        View in: PubMed
      88. Hicks C. Meeting notes from the 3rd IAS Conference. Old drugs, new data. AIDS Clin Care. 2005 Oct; 17(10):94-5. PMID: 16276589.
        View in: PubMed
      89. Sempowski GD, Hicks C, Eron JJ, Bartlett JA, Hale LP, Ferrari G, Edwards LJ, Fiscus S, Haynes BF. Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function. J Clin Immunol. 2005 Sep; 25(5):462-72. PMID: 16160915.
        View in: PubMed
      90. Kaplan SS, Hicks C. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection. Expert Opin Pharmacother. 2005 Aug; 6(9):1573-85. PMID: 16086645.
        View in: PubMed
      91. Kaplan SS, Hicks C. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother. 2005 Aug; 56(2):273-6. PMID: 15994247.
        View in: PubMed
      92. Hicks C. Report from the 12th Retrovirus Conference. Acute and recent HIV infection. AIDS Clin Care. 2005 Apr; 17(4):33-4. PMID: 15875306.
        View in: PubMed
      93. Kaplan SS, Ferrari G, Wrin T, Hellmann NS, Tomaras GD, Gryszowka VE, Fiscus SA, Weinhold KJ, Hicks C. Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. AIDS Res Hum Retroviruses. 2005 Jan; 21(1):13-6. PMID: 15665640.
        View in: PubMed
      94. Ritola K, Pilcher CD, Fiscus SA, Hoffman NG, Nelson JA, Kitrinos KM, Hicks C, Eron JJ, Swanstrom R. Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol. 2004 Oct; 78(20):11208-18. PMID: 15452240.
        View in: PubMed
      95. Hicks C, King MS, Gulick RM, White AC, Eron JJ, Kessler HA, Benson C, King KR, Murphy RL, Brun SC. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004 Mar 26; 18(5):775-9. PMID: 15075512.
        View in: PubMed
      96. Freel SA, Fiscus SA, Pilcher CD, Menezes P, Giner J, Patrick E, Lennox JL, Hicks C, Eron JJ, Shugars DC. Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. AIDS. 2003 Sep 26; 17(14):2025-33. PMID: 14502005.
        View in: PubMed
      97. Weintrob AC, Giner J, Menezes P, Patrick E, Benjamin DK, Lennox J, Pilcher CD, Eron JJ, Hicks C. Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med. 2003 Sep 22; 163(17):2097-100. PMID: 14504125.
        View in: PubMed
      98. Hicks C, Beckwith CG, Mitty J, Flanigan TP. Confronting the clinical uncertainty regarding syphilis. AIDS Clin Care. 2003 Jul; 15(7):64-5. PMID: 12913954.
        View in: PubMed
      99. Hicks C, Currier J, Sax P, Sherer R, Wanke C. Current management challenges in HIV: tolerability of antiretrovirals and metabolic complications. AIDS Patient Care STDS. 2003 May; 17(5):221-33. PMID: 12816616.
        View in: PubMed
      100. Hicks C, Montaner JS, Baker R, Youle M. Selected topics from the 10th Conference on Retroviruses and Opportunistic Infections. HIV Clin Trials. 2003 May-Jun; 4(3):202-26. PMID: 12815560.
        View in: PubMed
      101. Sufka SA, Ferrari G, Gryszowka VE, Wrin T, Fiscus SA, Tomaras GD, Staats HF, Patel DD, Sempowski GD, Hellmann NS, Weinhold KJ, Hicks C. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infect Dis. 2003 Apr 1; 187(7):1027-37. PMID: 12660916.
        View in: PubMed
      102. Hicks C, Feinberg J. Antiretroviral rounds. "Doc, I've been making mistakes". AIDS Clin Care. 2002 Dec; 14(12):108-9. PMID: 12510659.
        View in: PubMed
      103. Taiwo BO, Hicks C. Primary human immunodeficiency virus. South Med J. 2002 Nov; 95(11):1312-7. PMID: 12539999.
        View in: PubMed
      104. Bohjanen PR, Johnson MD, Szczech LA, Wray DW, Petros WP, Miller CR, Hicks C. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother. 2002 Aug; 46(8):2387-92. PMID: 12121909.
        View in: PubMed
      105. Pilcher CD, McPherson JT, Leone PA, Smurzynski M, Owen-O'Dowd J, Peace-Brewer AL, Harris J, Hicks C, Eron JJ, Fiscus SA. Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA. 2002 Jul 10; 288(2):216-21. PMID: 12095386.
        View in: PubMed
      106. Pilcher CD, Wohl DA, Hicks C. Diagnosing primary HIV infection. Ann Intern Med. 2002 Mar 19; 136(6):488-9; author reply 488-9. PMID: 11900505.
        View in: PubMed
      107. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002 Mar 1; 185(5):599-607. PMID: 11865416.
        View in: PubMed
      108. Fowler VG, Maxwell GL, Myers SA, Shea CR, Livengood CN, Prieto VG, Hicks C. Failure of benzathine penicillin in a case of seronegative secondary syphilis in a patient with acquired immunodeficiency syndrome: case report and review of the literature. Arch Dermatol. 2001 Oct; 137(10):1374-6. PMID: 11594871.
        View in: PubMed
      109. Pilcher CD, Shugars DC, Fiscus SA, Miller WC, Menezes P, Giner J, Dean B, Robertson K, Hart CE, Lennox JL, Eron JJ, Hicks C. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS. 2001 May 4; 15(7):837-45. PMID: 11399956.
        View in: PubMed
      110. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA. 2001 Mar 7; 285(9):1155-63. PMID: 11231744.
        View in: PubMed
      111. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White AC, Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001 Jan 5; 15(1):F1-9. PMID: 11192874.
        View in: PubMed
      112. Dunne M, Fessel J, Kumar P, Dickenson G, Keiser P, Boulos M, Mogyros M, White Jr AC, Cahn P, O'Connor M, Lewi D, Green S, Tilles J, Hicks C, Bissett J, Schneider MM, Benner R. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis. 2000 Nov; 31(5):1245-52. PMID: 11073759.
        View in: PubMed
      113. Henry K, Hicks C. Antiretroviral rounds. Reason to be worried. AIDS Clin Care. 2000 Oct; 12(10):82-3. PMID: 12211167.
        View in: PubMed
      114. Markert ML, Hicks C, Bartlett JA, Harmon JL, Hale LP, Greenberg ML, Ferrari G, Ottinger J, Boeck A, Kloster AL, McLaughlin TM, Bleich KB, Ungerleider RM, Lyerly HK, Wilkinson WE, Rousseau FS, Heath-Chiozzi ME, Leonard JM, Haase AT, Shaw GM, Bucy RP, Douek DC, Koup RA, Haynes BF, Bolognesi DP, Weinhold KJ. Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. AIDS Res Hum Retroviruses. 2000 Mar 20; 16(5):403-13. PMID: 10772526.
        View in: PubMed
      115. Fowler VG, Hicks C, Kirkland KB. The name game: lamivudine-lamotrigine dispensing error presenting as human immunodeficiency virus-associated fever of unknown origin. Int J STD AIDS. 1999 Oct; 10(10):685-6. PMID: 10582639.
        View in: PubMed
      116. Talbot EA, Hicks C. Opportunistic thoracic infections. Bacteria, viruses, and protozoa. Chest Surg Clin N Am. 1999 Feb; 9(1):167-92, ix-x. PMID: 10079986.
        View in: PubMed
      117. Bartlett JA, Wasserman SS, Hicks C, Dodge RT, Weinhold KJ, Tacket CO, Ketter N, Wittek AE, Palker TJ, Haynes BF. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. AIDS. 1998 Jul 30; 12(11):1291-300. PMID: 9708408.
        View in: PubMed
      118. Wang S, Sdrulla AD, diSibio G, Bush G, Nofziger D, Hicks C, Weinmaster G, Barres BA. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron. 1998 Jul; 21(1):63-75. PMID: 9697852.
        View in: PubMed
      119. Hicks C. Update on antiretroviral therapy. Radiol Clin North Am. 1997 Sep; 35(5):995-1005. PMID: 9298086.
        View in: PubMed
      120. Heald AE, Hicks C. Clinical complications of HIV infection. Radiol Clin North Am. 1997 Sep; 35(5):1007-27. PMID: 9298087.
        View in: PubMed
      121. Hicks C, Myers SA, Giner J. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. Clin Infect Dis. 1997 May; 24(5):1023-5. PMID: 9142826.
        View in: PubMed
      122. Stamm WE, Hicks C, Martin DH, Leone P, Hook EW, Cooper RH, Cohen MS, Batteiger BE, Workowski K, McCormack WM. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. JAMA. 1995 Aug 16; 274(7):545-9. PMID: 7629982.
        View in: PubMed
      123. Johnson SC, Stamm CP, Hicks C. Tuberculous psoas muscle abscess following chemoprophylaxis with isoniazid in a patient with human immunodeficiency virus infection. Rev Infect Dis. 1990 Sep-Oct; 12(5):754-6. PMID: 2237113.
        View in: PubMed
      124. Boslego JW, Hicks C, Greenup R, Thomas RJ, Wiener HA, Ciak J, Tramont EC. A prospective randomized trial of ofloxacin vs. doxycycline in the treatment of uncomplicated male urethritis. Sex Transm Dis. 1988 Oct-Dec; 15(4):186-91. PMID: 3147522.
        View in: PubMed
      125. Hicks C, Benson PM, Lupton GP, Tramont EC. Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma. Ann Intern Med. 1987 Oct; 107(4):492-5. PMID: 3307583.
        View in: PubMed
      126. Hicks C, Boslego JW, Brandt B. Evidence of serum antibodies to Neisseria gonorrhoeae before gonococcal infection. J Infect Dis. 1987 Jun; 155(6):1276-81. PMID: 2883240.
        View in: PubMed
      127. Hicks C, Abraham K. Verapamil and myoclonic dystonia. Ann Intern Med. 1985 Jul; 103(1):154. PMID: 4003975.
        View in: PubMed
      Charles's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _